132 related articles for article (PubMed ID: 29995287)
1. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
Ikeda M; Ohno I; Ueno H; Mitsunaga S; Hashimoto Y; Okusaka T; Kondo S; Sasaki M; Sakamoto Y; Takahashi H; Hara R; Kobayashi S; Nakamura O; Morizane C
Invest New Drugs; 2019 Feb; 37(1):109-117. PubMed ID: 29995287
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Ueno M; Morizane C; Furukawa M; Sakai D; Komatsu Y; Nakai Y; Tsuda M; Ozaka M; Mizuno N; Muto M; Fukutomi A; Ikeda M; Tsuji A; Katanuma A; Moriwaki T; Kajiwara T; Ishii H; Negoro Y; Shimizu S; Nemoto N; Kobayashi S; Makino K; Furuse J
Cancer Med; 2021 Mar; 10(6):2088-2099. PubMed ID: 33635605
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo M
Invest New Drugs; 2018 Dec; 36(6):1072-1084. PubMed ID: 30198057
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
6. Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Iwahashi S; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Saito Y; Ishikawa D; Shimada M
Anticancer Res; 2014 Sep; 34(9):5187-91. PubMed ID: 25202113
[TBL] [Abstract][Full Text] [Related]
7. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Bitzer M; Horger M; Giannini EG; Ganten TM; Wörns MA; Siveke JT; Dollinger MM; Gerken G; Scheulen ME; Wege H; Zagonel V; Cillo U; Trevisani F; Santoro A; Montesarchio V; Malek NP; Holzapfel J; Herz T; Ammendola AS; Pegoraro S; Hauns B; Mais A; Lauer UM; Henning SW; Hentsch B
J Hepatol; 2016 Aug; 65(2):280-8. PubMed ID: 26952006
[TBL] [Abstract][Full Text] [Related]
8. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
9. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of resminostat in Japanese patients with advanced solid tumors.
Kitazono S; Fujiwara Y; Nakamichi S; Mizugaki H; Nokihara H; Yamamoto N; Yamada Y; Inukai E; Nakamura O; Tamura T
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1155-61. PubMed ID: 25847480
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
Kim YJ; Im SA; Kim HG; Oh SY; Lee KW; Choi IS; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Kim SW; Heo DS; Yoon YB; Bang YJ
Ann Oncol; 2008 Jan; 19(1):99-103. PubMed ID: 17846018
[TBL] [Abstract][Full Text] [Related]
12. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer.
Shinchi H; Maemura K; Mataki Y; Kurahara H; Sakoda M; Ueno S; Hiraki Y; Nakajo M; Natsugoe S; Takao S
J Hepatobiliary Pancreat Sci; 2012 Mar; 19(2):152-8. PubMed ID: 21647560
[TBL] [Abstract][Full Text] [Related]
14. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).
Nakachi K; Konishi M; Ikeda M; Mizusawa J; Eba J; Okusaka T; Ishii H; Fukuda H; Furuse J;
Jpn J Clin Oncol; 2018 Apr; 48(4):392-395. PubMed ID: 29462482
[TBL] [Abstract][Full Text] [Related]
15. S-1 monotherapy in patients with advanced biliary tract cancer.
Sasaki T; Isayama H; Yashima Y; Yagioka H; Kogure H; Arizumi T; Togawa O; Matsubara S; Ito Y; Nakai Y; Sasahira N; Hirano K; Tsujino T; Tada M; Kawabe T; Omata M
Oncology; 2009; 77(1):71-4. PubMed ID: 19556812
[TBL] [Abstract][Full Text] [Related]
16. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction.
Yoon DH; Lee HJ; Hong YS; Kim KP; Lee SS; Lee JL; Chang HM; Ryu MH; Kang YK; Lee JS; Kim TW
Invest New Drugs; 2011 Apr; 29(2):332-9. PubMed ID: 20041339
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of S-1-based concurrent chemoradiotherapy in patients with biliary tract cancer.
Kim HM; Lee KJ; Cha J; Chung MJ; Bang S; Seong J; Song SY; Park SW
Cancer Chemother Pharmacol; 2014 Oct; 74(4):861-5. PubMed ID: 25129491
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
